Cargando…
Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein
Canocapavir is a novel antiviral agent with characteristics of core protein allosteric modulators (CpAMs) that is currently in a phase II clinical trial for treatment of hepatitis B virus (HBV) infection. Herein, we show that Canocapavir prevented the encapsidation of HBV pregenomic RNA and increase...
Autores principales: | Zheng, Yuan, Yang, Le, Yu, Lin, Zhu, Yuanfei, Wu, Yang, Zhang, Zhijun, Xia, Tian, Deng, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223407/ https://www.ncbi.nlm.nih.gov/pubmed/37243280 http://dx.doi.org/10.3390/v15051195 |
Ejemplares similares
-
Targeting the HIV-1 and HBV Capsids, an EnCore
por: McFadden, William M., et al.
Publicado: (2023) -
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial
por: Jia, Haiyan, et al.
Publicado: (2023) -
Allosteric conformational changes of human HBV core protein transform its assembly
por: Liu, Chuang, et al.
Publicado: (2017) -
Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives
por: Taverniti, Valerio, et al.
Publicado: (2022) -
Structure-Based Discovery of N-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication
por: Yang, Yang, et al.
Publicado: (2022)